Analytical quantification of aortic valve 18F-sodium fluoride PET uptake.
Aged
Algorithms
Aortic Valve
/ diagnostic imaging
Female
Fluorine Radioisotopes
Humans
Image Processing, Computer-Assisted
/ methods
Male
Middle Aged
Motion
Observer Variation
Positron Emission Tomography Computed Tomography
/ methods
Reproducibility of Results
Signal-To-Noise Ratio
Sodium Fluoride
Software
User-Computer Interface
Positron emission tomography
cardiac motion
computed tomography
valvular disease
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
01
10
2018
accepted:
07
11
2018
pubmed:
1
12
2018
medline:
31
8
2021
entrez:
1
12
2018
Statut:
ppublish
Résumé
Challenges to cardiac PET-CT include patient motion, prolonged image acquisition and a reduction of counts due to gating. We compared two analytical tools, FusionQuant and OsiriX, for quantification of gated cardiac 18F-sodium fluoride (18F-fluoride) PET-CT imaging. Twenty-seven patients with aortic stenosis were included, 15 of whom underwent repeated imaging 4 weeks apart. Agreement between analytical tools and scan-rescan reproducibility was determined using the Bland-Altman method and Lin's concordance correlation coefficients (CCC). Image analysis was faster with FusionQuant [median time (IQR) 7:10 (6:40-8:20) minutes] compared with OsiriX [8:30 (8:00-10:10) minutes, p = .002]. Agreement of uptake measurements between programs was excellent, CCC = 0.972 (95% CI 0.949-0.995) for mean tissue-to-background ratio (TBR 18F-fluoride PET quantification with FusionQuant and OsiriX is comparable. FusionQuant with motion correction offers advantages with respect to analysis time and reproducibility of TBR
Sections du résumé
BACKGROUND
Challenges to cardiac PET-CT include patient motion, prolonged image acquisition and a reduction of counts due to gating. We compared two analytical tools, FusionQuant and OsiriX, for quantification of gated cardiac 18F-sodium fluoride (18F-fluoride) PET-CT imaging.
METHODS
Twenty-seven patients with aortic stenosis were included, 15 of whom underwent repeated imaging 4 weeks apart. Agreement between analytical tools and scan-rescan reproducibility was determined using the Bland-Altman method and Lin's concordance correlation coefficients (CCC).
RESULTS
Image analysis was faster with FusionQuant [median time (IQR) 7:10 (6:40-8:20) minutes] compared with OsiriX [8:30 (8:00-10:10) minutes, p = .002]. Agreement of uptake measurements between programs was excellent, CCC = 0.972 (95% CI 0.949-0.995) for mean tissue-to-background ratio (TBR
CONCLUSION
18F-fluoride PET quantification with FusionQuant and OsiriX is comparable. FusionQuant with motion correction offers advantages with respect to analysis time and reproducibility of TBR
Identifiants
pubmed: 30499069
doi: 10.1007/s12350-018-01542-6
pii: 10.1007/s12350-018-01542-6
pmc: PMC6541558
mid: NIHMS998287
doi:
Substances chimiques
Fluorine Radioisotopes
0
Sodium Fluoride
8ZYQ1474W7
Fluorine-18
GZ5I74KB8G
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
962-972Subventions
Organisme : British Heart Foundation
ID : FS/14/78/31020
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : R01 HL135557
Pays : United States
Organisme : Wellcome Trust
ID : WT103782AIA
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/14/78
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701127
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/09/002
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/16/19/31982
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/10/32375
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/17/79/33226
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/13/3/30183
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/09/002/26360
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Références
Nat Commun. 2015 Jul 07;6:7495
pubmed: 26151378
Eur Heart J. 2013 Jun;34(21):1567-74
pubmed: 23391586
Curr Cardiol Rep. 2017 Feb;19(2):14
pubmed: 28185169
Clin Exp Pharmacol Physiol. 2010 Feb;37(2):143-9
pubmed: 19719745
Proc SPIE Int Soc Opt Eng. 2016 Feb 27;9784:
pubmed: 27212782
J Nucl Cardiol. 2010 Jun;17(3):414-26
pubmed: 20151238
Atherosclerosis. 2017 Aug;263:385-392
pubmed: 28528743
J Nucl Cardiol. 2018 Dec;25(6):2001-2011
pubmed: 28500539
Circulation. 2012 Jan 3;125(1):76-86
pubmed: 22090163
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
J Nucl Med. 2016 Jan;57(1):54-9
pubmed: 26471691
J Nucl Cardiol. 2020 Apr;27(2):494-504
pubmed: 29948889
Atherosclerosis. 2017 May;260:41-46
pubmed: 28349887
J Nucl Cardiol. 2019 Aug;26(4):1064-1075
pubmed: 29943142
Med Image Comput Comput Assist Interv. 2008;11(Pt 1):754-61
pubmed: 18979814
Circ Cardiovasc Imaging. 2016 Oct;9(10):
pubmed: 27733431
JACC Cardiovasc Imaging. 2016 May;9(5):627-8
pubmed: 26189122
J Nucl Cardiol. 2013 Aug;20(4):569-77
pubmed: 23588862
J Am Coll Cardiol. 2012 Apr 24;59(17):1539-48
pubmed: 22516444
Semin Nucl Med. 1972 Jan;2(1):31-7
pubmed: 5059349
J Am Coll Cardiol. 2018 Feb 06;71(5):513-523
pubmed: 29406857
J Nucl Med. 2010 Jun;51(6):862-5
pubmed: 20484438
J Nucl Cardiol. 2018 Oct;25(5):1774-1783
pubmed: 29992525
J Nucl Cardiol. 2018 Oct;25(5):1742-1756
pubmed: 28176255
J Nucl Med. 2017 Nov;58(11):1811-1814
pubmed: 28546334
J Nucl Med. 2011 Mar;52(3):362-8
pubmed: 21321276